Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0649

0.0%

3:58 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Howard Williams	9/6/2013 11:16:51 AM
	of 13111

Lengthy positive article on SeekingAlpha re PVCT seekingalpha.com Provectus Pharmaceuticals: Small Cap, Huge Upside Sep 6 2013, 10:25 EXECUTIVE SUMMARY Provectus ( PVCT.OB) is a small biotech company whose lead candidate, PV-10 has been granted FDA Orphan Drug Status for the treatment of highly lethal metastatic melanoma and metastatic liver cancer. It has a successful and expanding Compassionate Use program in operation and successfully completed trials on metastatic cancer of the breast, liver and melanoma, with positive results. The data suggest that intralesional injection kills cancer cells and not normal cells, with no debilitating side-effects. As if that is not enough, a single injection acts as immunotherapy, prompting the patient's immune system to attack tumors remote from the one injected. Given that PV-10 has an outstanding safety profile, no debilitating treatment side effects, and has been effective in treating solid tumors that normally have a high mortality rate, the remarkably low market capitalization makes the investment premise obvious. Read it all at the link.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next